Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.

Saved in:
Bibliographic Details
Title: Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.
Authors: Thiebaut C; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Martinez S; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Pruvost L; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Eve L; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., El-Botty R; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Sourd L; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Montaudon E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Dahmani A; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Derrien H; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Sentis S; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Poulard C; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Marangoni E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Trédan O; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Oncology Department, Centre Leon Bérard, Lyon, France., Le Romancer M; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Source: Cancer science [Cancer Sci] 2026 May; Vol. 117 (5), pp. 1273-1285. Date of Electronic Publication: 2026 Mar 09.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41801765
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Thiebaut+C%22">Thiebaut C</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Martinez+S%22">Martinez S</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Pruvost+L%22">Pruvost L</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Eve+L%22">Eve L</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22El-Botty+R%22">El-Botty R</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sourd+L%22">Sourd L</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Montaudon+E%22">Montaudon E</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Dahmani+A%22">Dahmani A</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Derrien+H%22">Derrien H</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sentis+S%22">Sentis S</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Poulard+C%22">Poulard C</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Marangoni+E%22">Marangoni E</searchLink>; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France.<br /><searchLink fieldCode="AU" term="%22Trédan+O%22">Trédan O</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Oncology Department, Centre Leon Bérard, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Le+Romancer+M%22">Le Romancer M</searchLink>; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101168776%22">Cancer science</searchLink> [Cancer Sci] 2026 May; Vol. 117 (5), pp. 1273-1285. <i>Date of Electronic Publication: </i>2026 Mar 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley+Publishing+on+behalf+of+the+Japanese+Cancer+Association%22">Wiley Publishing on behalf of the Japanese Cancer Association </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101168776 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1349-7006 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213479032%22">13479032 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Sci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41801765
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/cas.70338
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1273
    Titles:
      – TitleFull: Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Thiebaut C
      – PersonEntity:
          Name:
            NameFull: Martinez S
      – PersonEntity:
          Name:
            NameFull: Pruvost L
      – PersonEntity:
          Name:
            NameFull: Eve L
      – PersonEntity:
          Name:
            NameFull: El-Botty R
      – PersonEntity:
          Name:
            NameFull: Sourd L
      – PersonEntity:
          Name:
            NameFull: Montaudon E
      – PersonEntity:
          Name:
            NameFull: Dahmani A
      – PersonEntity:
          Name:
            NameFull: Derrien H
      – PersonEntity:
          Name:
            NameFull: Sentis S
      – PersonEntity:
          Name:
            NameFull: Poulard C
      – PersonEntity:
          Name:
            NameFull: Marangoni E
      – PersonEntity:
          Name:
            NameFull: Trédan O
      – PersonEntity:
          Name:
            NameFull: Le Romancer M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1349-7006
          Numbering:
            – Type: volume
              Value: 117
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Cancer science
              Type: main
ResultId 1